天新药业2024年归母净利润增36.9%至6.51亿元

财中社2025-04-25

4月25日，天新药业(603235)公布2024年年报，公司营业收入为22.1亿元，同比上升17.4%；归母净利润为6.51亿元，同比上升36.9%；扣非归母净利润为6.14亿元，同比上升42.5%；经营现金流净额为5.0亿元，同比下降31.5%；EPS(全面摊薄)为1.4876元。其中第四季度，公司营业收入为5.95亿元，同比上升50.8%；归母净利润为1.57亿元，同比上升149.0%；扣非...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530297434?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-25 16:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530297434","market":"sh","top_or_hot":-1,"title":"天新药业2024年归母净利润增36.9%至6.51亿元","media":"财中社","content":"<div>\n<p>4月25日，天新药业(603235)公布2024年年报，公司营业收入为22.1亿元，同比上升17.4%；归母净利润为6.51亿元，同比上升36.9%；扣非归母净利润为6.14亿元，同比上升42.5%；经营现金流净额为5.0亿元，同比下降31.5%；EPS(全面摊薄)为1.4876元。其中第四季度，公司营业收入为5.95亿元，同比上升50.8%；归母净利润为1.57亿元，同比上升149.0%；扣非...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251610049744b75b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天新药业2024年归母净利润增36.9%至6.51亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天新药业2024年归母净利润增36.9%至6.51亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 16:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251610049744b75b&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月25日，天新药业(603235)公布2024年年报，公司营业收入为22.1亿元，同比上升17.4%；归母净利润为6.51亿元，同比上升36.9%；扣非归母净利润为6.14亿元，同比上升42.5%；经营现金流净额为5.0亿元，同比下降31.5%；EPS(全面摊薄)为1.4876元。其中第四季度，公司营业收入为5.95亿元，同比上升50.8%；归母净利润为1.57亿元，同比上升149.0%；扣非...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251610049744b75b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603235","symbol_name":"天新药业","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251610049744b75b&s=b","article_id":"2530297434","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251610049744b75b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530297434","pubTimestamp":1745568420,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月25日，天新药业公布2024年年报，公司营业收入为22.1亿元，同比上升17.4%；归母净利润为6.51亿元，同比上升36.9%；扣非归母净利润为6.14亿元，同比上升42.5%；经营现金流净额为5.0亿元，同比下降31.5%；EPS为1.4876元。其中第四季度，公司营业收入为5.95亿元，同比上升50.8%；归母净利润为1.57亿元，同比上升149.0%；扣非归母净利润为1.47亿元，同比上升178.2%；EPS为0.358元。报告期内，实现营业收入22.09亿元，归属于上市公司股东的净利润6.51亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"603235":"天新药业"},"translate_title":"Tianxin Pharmaceutical's net profit attributable to the parent company will increase by 36.9% to 651 million yuan in 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603235":1},"content_text":"4月25日，天新药业(603235)公布2024年年报，公司营业收入为22.1亿元，同比上升17.4%；归母净利润为6.51亿元，同比上升36.9%；扣非归母净利润为6.14亿元，同比上升42.5%；经营现金流净额为5.0亿元，同比下降31.5%；EPS(全面摊薄)为1.4876元。其中第四季度，公司营业收入为5.95亿元，同比上升50.8%；归母净利润为1.57亿元，同比上升149.0%；扣非归母净利润为1.47亿元，同比上升178.2%；EPS为0.358元。截至四季度末，公司总资产56.03亿元，较上年度末增长10.1%；归母净资产为46.16亿元，较上年度末增长9.0%。2024年度的经营业务中，维生素行业呈现出较强的发展韧性，市场需求温和复苏，部分维生素产品价格触底回升，行业盈利能力有所恢复。在此背景下，专注主业经营，推动创新驱动和高质量发展，构建产业链矩阵，巩固竞争优势。报告期内，实现营业收入22.09亿元，归属于上市公司股东的净利润6.51亿元。具体的经营工作中，聚焦客户价值，提升经营质量。随着下游需求的复苏，维生素行业的景气度有所回升，维生素B6和维生素B1等产品价格上涨，但同质化竞争仍是企业面临的挑战。通过差异化竞争策略，优化产品组合，增强客户粘性，并推出了维生素B5和维生素A等新产品，进一步丰富了产品线。同时，加速建设宁夏生产基地和相关中间体项目，以降低原料成本，提升产品竞争力。此外，完善质量管理体系方面持续努力，推动产品注册认证工作，确保产品安全和质量。积极探索智能化生产模式，提升生产效率和管理效能，以适应市场变化。整体来看，经营策略和市场应对措施为其在维生素行业的持续发展奠定了良好基础。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530297434","isCrawlerRequest":true}